---
title: Reduce tremor slowness and stiffness
nct_id: NCT07348705
phase: NA
status: RECRUITING
sponsor: University of Florida
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07348705"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07348705"
last_fetched: "2026-05-10T14:05:49.316Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce tremor slowness and stiffness

**Goal (in five words):** Reduce tremor slowness and stiffness

**Official Title:** Electrophysiology-based Deep Brain Stimulation Programming for Parkinson's Disease

**Trial ID:** [NCT07348705](https://clinicaltrials.gov/study/NCT07348705)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** University of Florida
- **Target Enrollment:** 30 participants
- **Start Date:** 2026-01-15
- **Completion Date:** 2027-01-15
- **Conditions:** Parkinson's Disease (PD)
- **Interventions:** Clinician-based DBS programming, Maximum Beta power-based DBS programming, Broad-band electrophysiology-based DBS programming
- **Intervention Types:** DEVICE

## Summary For Families

The team wants to know if using the brain's own electrical signals to guide deep brain stimulation can give more precise, faster relief of motor symptoms like tremor, slowness, and stiffness than usual clinician-led programming. Using the Medtronic Percept DBS, the study compares standard clinician programming to two signal-guided methods, one that sets stimulation where beta-band power is highest and one that uses broader electrophysiology patterns, with the goal of reducing abnormal brain oscillations while patients continue their regular medications. Adults 21 to 89 with idiopathic Parkinson’s who already have a Percept DBS implanted and can consent at their initial programming session are eligible; people with atypical parkinsonism or who cannot follow the protocol are excluded.

## Eligibility

- **Minimum age:** 21 Years
- **Maximum age:** 89 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Patients with a diagnosis of idiopathic PD fulfilling the Movement Disorder Society Clinical Diagnostic Criteria for PD
* DBS implantation with the Percept DBS device (Medtronic, USA) for the treatment of motor symptoms
* Ability to give informed consent for the study
* Willingness to do this study at the time of the initial programming session
* Age 21 to 89 years old

Exclusion Criteria:

* Inability to comply with the study protocol
* Atypical Parkinsonism
* Any personality or mood symptoms that study personnel believe will interfere with the study requirements
```

## Locations (1)

- Norman Fixel Institute for Neurological Diseases, Gainesville, Florida, United States _(29.6516, -82.3248)_
  - Hikaru Kamo, MD, PhD — (CONTACT) — Hikaru.Kamo@neurology.ufl.edu
  - Julia C Gonzalez, BA — (CONTACT) — Julia.Gonzalez@neurology.ufl.edu
  - Joshua Wong, MD — (PRINCIPAL_INVESTIGATOR)
  - Hikaru Kamo, MD, PhD — (SUB_INVESTIGATOR)

## Central Contacts

- Joshua Wong, MD — (CONTACT) — 352-294-5400 — Joshua.Wong@neurology.ufl.edu

---

*Canonical: https://parkinsonspathways.com/trial/NCT07348705*  
*HTML version: https://parkinsonspathways.com/trial/NCT07348705*  
*Source data: https://clinicaltrials.gov/study/NCT07348705*